Watch IBO. Know when insiders buy.
One email the day a filing lands. Free.
IBO
IMPACT BIOMEDICAL INC.
0.57
+0.07 +14.66%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
54
WATCH · shorts 54
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $61.6MP/E 0.6DIV YIELD —FCF YIELD —REV TTM $35KNET INCOME $789KNET DEBT $11.9M52W 0.40 – 0.78SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $3K | −57.1% | 66.7% | −$702K | −$699K | — | -0.01 | $470K | — | — | Aug 7 |
| Q1 2026 · Mar 31 | $7K | — | — | −$2.3M | −$2.3M | — | -0.02 | −$464K | — | — | May 12 |
| Q4 2025 · Dec 31derived | $7K | — | -5928.6% | −$1.2M | $5.2M | — | 1.03 | $99K | — | — | Mar 11 |
| Q3 2025 · Sep 30 | $18K | — | 94.4% | −$948K | −$1.5M | −134.6% | -0.12 | −$613K | — | — | Nov 7 |
| Q2 2025 · Jun 30 | $7K | — | 85.7% | −$1.2M | −$14.3M | — | -1.18 | −$694K | — | — | Aug 7 |
| Q1 2025 · Mar 31 | — | — | — | −$1M | −$1.3M | — | -0.11 | −$682K | — | — | May 12 |
| Q4 2024 · Dec 31derived | — | — | — | −$26.2M | −$27.1M | — | -2.33 | −$986K | — | — | Mar 11 |
| Q3 2024 · Sep 30 | — | — | — | −$1.1M | $4.2M | — | 0.06 | −$1M | — | — | Nov 7 |
| Q2 2024 · Jun 30 | — | — | — | −$626K | −$889K | — | -0.09 | −$385K | — | — | Aug 14 |
| Q1 2024 · Mar 31 | — | — | — | −$771K | −$962K | — | -0.10 | −$482K | — | — | May 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$1.1M | −$1.2M | — | -0.03 | −$433K | — | — | Mar 28 |
| Q3 2023 · Sep 30 | — | — | — | −$1.1M | −$1.2M | — | -0.02 | −$671K | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $32K | -1225.0% | −$4.3M | −$11.8M | -36993.8% | -0.38 | −$1.9M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$28.8M | −$24.7M | — | -2.30 | −$2.9M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$4M | −$4.3M | — | -0.07 | −$2.9M | — | — | — | — |
| FY2022 · to Dec 31 | $50K | — | −$3.4M | −$7.3M | -14510.0% | -0.10 | −$2.2M | — | — | — | — |
Every number comes from IMPACT BIOMEDICAL INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.